TY - JOUR
T1 - Invasive breast cancer version 1.2016
AU - Gradishar, William J.
AU - Anderson, Benjamin O.
AU - Balassanian, Ron
AU - Blair, Sarah L.
AU - Burstein, Harold J.
AU - Cyr, Amy
AU - Elias, Anthony D.
AU - Farrar, William B.
AU - Forero, Andres
AU - Giordano, Sharon Hermes
AU - Goetz, Matthew
AU - Goldstein, Lori J.
AU - Hudis, Clifford A.
AU - Isakoff, Steven J.
AU - Kelly Marcom, P.
AU - Mayer, Ingrid A.
AU - McCormick, Beryl
AU - Moran, Meena
AU - Patel, Sameer A.
AU - Pierce, Lori J.
AU - Reed, Elizabeth C.
AU - Salerno, Kilian E.
AU - Schwartzberg, Lee S.
AU - Smith, Karen Lisa
AU - Smith, Mary Lou
AU - Soliman, Hatem
AU - Somlo, George
AU - Telli, Melinda
AU - Ward, John H.
AU - Shead, Dorothy A.
AU - Kumar, Rashmi
N1 - Publisher Copyright:
© JNCCN - Journal of the National Comprehensive Cancer Network.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. This article outlines the NCCN Guidelines specific to breast cancer that is locoregional (restricted to one region of the body), and discusses the management of clinical stage I, II, and IIIA (T3N1M0) tumors. For NCCN Guidelines on systemic adjuvant therapy after locoregional management of clinical stage I, II and IIIA (T3N1M0) and for management for other clinical stages of breast cancer, see the complete version of these guidelines at NCCN.org.
AB - Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. This article outlines the NCCN Guidelines specific to breast cancer that is locoregional (restricted to one region of the body), and discusses the management of clinical stage I, II, and IIIA (T3N1M0) tumors. For NCCN Guidelines on systemic adjuvant therapy after locoregional management of clinical stage I, II and IIIA (T3N1M0) and for management for other clinical stages of breast cancer, see the complete version of these guidelines at NCCN.org.
UR - http://www.scopus.com/inward/record.url?scp=84961577176&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2016.0037
DO - 10.6004/jnccn.2016.0037
M3 - Review article
C2 - 26957618
AN - SCOPUS:84961577176
SN - 1540-1405
VL - 14
SP - 324
EP - 354
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 3
ER -